The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. has published early results for its OCU410ST clinical trial, revealing a 54 percent reduction in the growth of atrophic lesions among treated patients.
According to the company, 100 percent of treated eyes either stabilized or improved, with participants reporting an average gain of six letters in visual acuity. These initial findings highlight the strong potential of OCU410ST in addressing atrophic eye conditions. An insight from a clinical trial participant is available through the company’s provided resources.
Ocugen is developing OCU410ST as part of its efforts to address inherited retinal diseases lacking approved therapies. The company previously reported early-stage gene therapy progress for approximately 100,000 patients with Stargardt disease who have no FDA-approved treatment options. Ocugen has also launched a modifier gene therapy platform targeting advanced retinal diseases at several industry conferences focused on solutions for inherited blindness.